Peter L Turecek
Overview
Explore the profile of Peter L Turecek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1074
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siffel C, Wadhwa A, Tongbram V, Ogongo M, Sliwka H, Gazda H, et al.
Res Pract Thromb Haemost
. 2024 Sep;
8(6):102542.
PMID: 39286606
Severe congenital protein C deficiency (SCPCD) is a rare disorder associated with life-threatening purpura fulminans and disseminated intravascular coagulation that typically present within hours after birth. Treatment options for patients...
2.
Schachinger T, Holik A, Schrenk G, Gritsch H, Hofbauer S, Furtmuller P, et al.
Bio Protoc
. 2024 Sep;
14(17):e5059.
PMID: 39282235
Accurate quantification of von Willebrand factor ristocetin cofactor activity (VWF:RCo) is critical for the diagnosis and classification of von Willebrand disease, the most common hereditary and acquired bleeding disorder in...
3.
Igrutinovic Z, Hooimeijer H, Kentouche K, Botha J, Turecek P, Kokot-Kierepa M, et al.
J Blood Med
. 2024 Mar;
15:113-122.
PMID: 38481741
Introduction: Purified factor IX (FIX) concentrate (IMMUNINE, Takeda Manufacturing Austria AG, Vienna, Austria) is indicated for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia B. Data...
4.
Holle L, Pantazis J, Turecek P, Wolberg A
Res Pract Thromb Haemost
. 2024 Mar;
8(1):102337.
PMID: 38426025
Background: Measuring the activity of hemostatic agents used to treat hemophilia A often requires drug-specific assays. assays show hemophilic clots have abnormal characteristics, including prolonged clotting time and decreased resistance...
5.
Turecek P, Ilk R, Gritsch H
Haemophilia
. 2023 Nov;
30(1):151-160.
PMID: 37926687
Introduction: Several well-established clinical laboratory methods are available to measure von Willebrand factor (VWF) in plasma samples, but few data are available on their use for analysing recombinant VWF (rVWF)....
6.
Valke L, Verhagen M, Mulders B, Polenewen R, Blijlevens N, Jansen J, et al.
Thromb Res
. 2023 Oct;
231:112-120.
PMID: 37844518
Background: An inhibitor can develop in congenital hemophilia A (HA) patients against exogenous infused factor (F)VIII, whereas in acquired HA (AHA) inhibitors initially develop against endogenous FVIII. Inhibitors can be...
7.
Pezeshkpoor B, Sereda N, Berkemeier A, Matuschek I, Schwarz N, Turecek P, et al.
J Thromb Haemost
. 2023 Mar;
21(6):1503-1514.
PMID: 36934798
Background: The standard therapy for patients with hemophilia A (HA) is the replacement with factor VIII (FVIII) therapeutics. To overcome the limitation of short half-life of wild-type FVIII protein, polyethylene...
8.
Kennedy M, Roche S, McGowan M, Larkin N, OConnell N, OMahony B, et al.
Haemophilia
. 2023 Mar;
29(3):892-899.
PMID: 36912447
Aim: To conduct a cross-sectional follow-up assessment of physical activity (PA) in people with moderate and severe haemophilia (PwMSH) from the Irish Personalised Approach to the Treatment of Haemophilia (iPATH)...
9.
Elsheikh E, Lavin M, Antunes Heck L, Larkin N, Mullaney B, Doherty D, et al.
J Thromb Haemost
. 2023 Feb;
21(5):1123-1134.
PMID: 36775768
Background: Previous studies have reported marked interindividual variation in factor VIII (FVIII) clearance in patients with hemophilia (PWH) and proposed a number of factors that influence this heterogeneity. Objectives: To...
10.
Ward S, Guest T, Byrne C, Lopes P, OSullivan J, Doherty D, et al.
Arterioscler Thromb Vasc Biol
. 2023 Feb;
43(4):540-546.
PMID: 36727518
Background: Although most plasma FVIII (Factor VIII) circulates in complex with VWF (von Willebrand factor), a minority (3%-5%) circulates as free-FVIII, which is rapidly cleared. Consequently, 20% of total FVIII...